Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT (NCT06319131) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT
84 participantsStarted 2024-05-01
Plain-language summary
The purpose of this study is to evaluate the comparative effectiveness of nadroparin versus transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory asymptomatic portal vein thrombosis using a design of a multicenter, randomized controlled trial
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosed with liver cirrhosis
* Diagnosis of portal vein thrombosis through computed tomographic venography with a thrombus diameter exceeding 30% of the vessel diameter.
* Consent to participate in the clinical trial and the signing of an informed consent form.
Exclusion Criteria:
* Presence of acute symptoms such as fever, abdominal pain or bleeding, or of cavernous transformation
* Patients with Child-Pugh C.
* Pregnant or lactating women.
* With a history of liver cancer or other malignancy.
* Severe heart, lung diseases, or significant renal dysfunction.
* Allergies to anticoagulant medications, uncontrolled hypertension, history of cerebral hemorrhage, discovery of gastrointestinal ulcers, ulcerative colitis, subacute bacterial endocarditis, or other contraindications to anticoagulant drugs.
* On concomitant therapy of immunosuppressive drugs.
* With coagulation disorders other than liver disease.
* With active variceal bleeding.